3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Myeloid
4
Lymphoid
4
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
106
Specimen Handling
87
pembrolizumab
81
enzalutamide
64
Nivolumab
62
Gemcitabine
59
Docetaxel
51
Abiraterone Acetate
44
apalutamide
43
Radiosurgery
43
Androgen Antagonists
43
Prednisone
42
darolutamide
40
Cisplatin
38
Biopsy
36
Radiotherapy
34
cabozantinib
32
Carboplatin
30
abiraterone
29
Pluvicto
29
Ipilimumab
29
durvalumab
25
Leuprolide
24
enfortumab vedotin
23
X-Rays
23
Radiation
23
olaparib
20
atezolizumab
20
Standard of Care
20
avelumab
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Genitourinary
×
90 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled